Eliyahu Sharon Kalif - 05 Mar 2024 Form 4 Insider Report for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)

Role
EVP, Chief Financial Officer
Signature
/s/ Dov Bergwerk as attorney-in-fact for Eliyahu Sharon Kalif
Issuer symbol
TEVA
Transactions as of
05 Mar 2024
Net transactions value
-$1,048,119
Form type
4
Filing time
07 Mar 2024, 16:27:55 UTC
Previous filing
05 Mar 2024
Next filing
30 Jan 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TEVA Ordinary Shares Options Exercise +52,320 +25% 259,854 05 Mar 2024 Direct F1, F2
transaction TEVA Ordinary Shares Options Exercise +21,387 +8.2% 281,241 05 Mar 2024 Direct F1, F2
transaction TEVA Ordinary Shares Sale $1,048,119 -77,550 -28% $13.52 203,691 06 Mar 2024 Direct F1, F3, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TEVA Restricted Share Units Options Exercise $0 -21,387 -50% $0.000000 21,390 05 Mar 2024 Ordinary Shares 21,387 Direct F1, F2, F5
transaction TEVA Restricted Share Units Options Exercise $0 -52,320 -100% $0.000000* 0 05 Mar 2024 Ordinary Shares 52,320 Direct F1, F2, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F2 Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
F3 The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 27, 2023.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.41 to $13.61, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
F5 Restricted share units were granted on March 5, 2021, with 21,387 vesting on each of March 5, 2022, March 5, 2023, and March 5, 2024, and 21,390 vesting on March 5, 2025.
F6 Restricted share units were granted on January 30, 2024 pursuant to the satisfaction of performance criteria and vested on March 5, 2024.